- Home
- AGIO vs BUSE Comparison
AGIO vs BUSE Comparison
Compare AGIO & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BUSE
- Stock Information
- Founded
- AGIO 2007
- BUSE 1868
- Country
- AGIO United States
- BUSE United States
- Employees
- AGIO N/A
- BUSE N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BUSE Major Banks
- Sector
- AGIO Health Care
- BUSE Finance
- Exchange
- AGIO Nasdaq
- BUSE Nasdaq
- Market Cap
- AGIO 2.4B
- BUSE 2.1B
- IPO Year
- AGIO 2013
- BUSE N/A
- Fundamental
- Price
- AGIO $41.13
- BUSE $22.52
- Analyst Decision
- AGIO Strong Buy
- BUSE Buy
- Analyst Count
- AGIO 4
- BUSE 7
- Target Price
- AGIO $59.33
- BUSE $27.43
- AVG Volume (30 Days)
- AGIO 514.0K
- BUSE 440.7K
- Earning Date
- AGIO 10-30-2025
- BUSE 10-28-2025
- Dividend Yield
- AGIO N/A
- BUSE 4.44%
- EPS Growth
- AGIO N/A
- BUSE N/A
- EPS
- AGIO 11.13
- BUSE 1.27
- Revenue
- AGIO $40,875,000.00
- BUSE $583,913,000.00
- Revenue This Year
- AGIO $23.74
- BUSE $62.58
- Revenue Next Year
- AGIO $159.90
- BUSE $11.64
- P/E Ratio
- AGIO $3.77
- BUSE $17.78
- Revenue Growth
- AGIO 30.57
- BUSE 33.62
- 52 Week Low
- AGIO $23.42
- BUSE $18.40
- 52 Week High
- AGIO $62.58
- BUSE $28.30
- Technical
- Relative Strength Index (RSI)
- AGIO 50.11
- BUSE 41.27
- Support Level
- AGIO $41.24
- BUSE $22.37
- Resistance Level
- AGIO $44.25
- BUSE $23.55
- Average True Range (ATR)
- AGIO 1.52
- BUSE 0.65
- MACD
- AGIO -0.16
- BUSE -0.02
- Stochastic Oscillator
- AGIO 31.28
- BUSE 26.53
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.